SCHEMBL1496426

SCHEMBL1496426

COc1cc2nccc(CSc3ncccc3C(=O)O)c2cc1OC

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
GAA P10253 1/20 0.56
KDM4E B2RXH2 3/20 0.55
HTT P42858 1/20 0.55
TDP1 Q9NUW8 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
CYP2C9 P11712 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
TP53 P04637 1/20 0.50
HPGD P15428 2/20 0.49
SRC P12931 1/20 0.47
TGFBR1 P36897 1/20 0.47
PKM P14618 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496351 0.83 LMNA (0.52) ALDH1A1KDM4EHTTTDP1SMN1; SMN2
SCHEMBL1496421 0.83 MEN1 (0.65) ALDH1A1GAAKDM4EHTTMEN1
SCHEMBL1496337 0.81 ALDH1A1 (0.71) ALDH1A1GAAKDM4EHTTMEN1
SCHEMBL1496256 0.81 KDR (0.57) ALDH1A1KDM4ESMN1; SMN2TP53LMNA
SCHEMBL1496385 0.81 MEN1 (0.62) ALDH1A1GAAKDM4EHTTMEN1
SCHEMBL29952880 0.76 NPSR1 (0.62) ALDH1A1GAAKDM4EHTTTDP1
SCHEMBL4018474 0.74 SMN1; SMN2 (0.65) ALDH1A1GAAKDM4EHTTTDP1
SCHEMBL5940512 0.73 SRC (0.49) GAASRCTGFBR1HSD17B10
SCHEMBL9869842 0.71 KMT2A (0.68) ALDH1A1GAAKDM4EHTTTDP1
SCHEMBL12870286 0.71 ALDH1A1 (0.79) ALDH1A1GAAKDM4EHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897774-B2 Cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-01 US disclosed
EP-1854787-B1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2010-09-01 EP disclosed
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US disclosed
EP-1854787-A1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SQOR, QSOX1, SQLE ALDH1A1 1108/4885GAA 4244/4885KDM4E 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.